Trial Profile
A PHASE 1, RANDOMIZED, OPEN-LABEL, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE EFFECT OF PF-06865571 ON THE PHARMACOKINETICS OF METFORMIN IN HEALTHY ADULT SUBJECTS
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Ervogastat (Primary) ; Metformin
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 27 Mar 2019 Status changed from recruiting to completed.
- 24 Jan 2019 Planned End Date changed from 12 Feb 2019 to 13 Feb 2019.
- 14 Dec 2018 Status changed from suspended to recruiting.